Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.205 GBX | -7.31% | -19.67% | -24.69% |
05-03 | Physiomics warns large contracts taken longer than expected | AN |
05-03 | AIM WINNERS & LOSERS: Fletcher King optimistic; Angle in Astra deal | AN |
Valuation
Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Capitalization 1 | 2.265 | 6.643 | 6.229 | 2.874 | 0.9499 | 1.761 |
Enterprise Value (EV) 1 | 2.265 | 6.643 | 6.229 | 2.874 | 0.5333 | 1.581 |
P/E ratio | -22.5 x | -77.2 x | -29.1 x | -11.3 x | -1.99 x | -2.89 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 2.89 x | 7.89 x | 8.52 x | 3.19 x | 1.57 x | 2.82 x |
EV / Revenue | 2.89 x | 7.89 x | 8.52 x | 3.19 x | 0.88 x | 2.53 x |
EV / EBITDA | - | - | - | - | - | - |
EV / FCF | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 71,910 | 95,589 | 97,335 | 97,425 | 97,425 | 135,472 |
Reference price 2 | 0.0315 | 0.0695 | 0.0640 | 0.0295 | 0.009750 | 0.0130 |
Announcement Date | 30/09/19 | 30/09/20 | 30/09/21 | 29/09/22 | 28/09/23 | - |
Income Statement Evolution (Annual data)
Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Net sales 1 | 0.7831 | 0.8416 | 0.7309 | 0.9007 | 0.6057 | 0.625 |
EBITDA | - | - | - | - | - | - |
EBIT 1 | -0.2012 | -0.1344 | -0.337 | -0.3591 | -0.5737 | -0.675 |
Operating Margin | -25.7% | -15.97% | -46.11% | -39.87% | -94.72% | -108% |
Earnings before Tax (EBT) 1 | -0.2012 | -0.1337 | -0.3369 | -0.359 | -0.572 | -0.67 |
Net income 1 | -0.1045 | -0.0644 | -0.2158 | -0.2531 | -0.4773 | -0.61 |
Net margin | -13.35% | -7.65% | -29.53% | -28.1% | -78.79% | -97.6% |
EPS 2 | -0.001400 | -0.000900 | -0.002200 | -0.002600 | -0.004900 | -0.004500 |
Free Cash Flow | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 30/09/19 | 30/09/20 | 30/09/21 | 29/09/22 | 28/09/23 | - |
Balance Sheet Analysis
Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | - | - | - | - | 0.42 | 0.18 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - |
Capex 1 | 0.02 | 0.01 | 0.02 | 0.01 | 0 | 0 |
Capex / Sales | 2.96% | 0.6% | 2.21% | 1.04% | 0.54% | 0.32% |
Announcement Date | 30/09/19 | 30/09/20 | 30/09/21 | 29/09/22 | 28/09/23 | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-24.69% | 2.2M | |
-2.57% | 134B | |
+18.43% | 75.32B | |
+15.00% | 37.77B | |
-16.78% | 37.29B | |
-5.25% | 28.96B | |
-9.05% | 16.54B | |
+13.23% | 15.11B | |
+9.55% | 10.49B | |
-13.42% | 4.48B |
- Stock Market
- Equities
- PYC Stock
- Financials Physiomics Plc